{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T19:51:57Z","timestamp":1771357917970,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.soncn.2009.03.006","type":"journal-article","created":{"date-parts":[[2009,5,4]],"date-time":"2009-05-04T04:48:23Z","timestamp":1241412503000},"page":"120-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"25","author":[{"given":"Nonniekaye","family":"Shelburne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Bevans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.soncn.2009.03.006_bib1","first-page":"1","article-title":"Stem cell transplantation: past, present and future","volume":"45","author":"Thomas","year":"1997","journal-title":"Arch Immunol Ther Exp"},{"key":"10.1016\/j.soncn.2009.03.006_bib2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.critrevonc.2004.05.008","article-title":"Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens","volume":"51","author":"Banna","year":"2004","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.soncn.2009.03.006_bib3","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJM197504242921706","article-title":"Bone-marrow transplantation (second of two parts)","volume":"292","author":"Thomas","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2009.03.006_bib4","first-page":"18","article-title":"Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy","volume":"111","author":"Champlin","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.soncn.2009.03.006_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/beha.2001.0168","article-title":"Allogeneic transplantation using non-myeloablative transplant regimens","volume":"14","author":"Battiwalla","year":"2001","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.soncn.2009.03.006_bib6","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/blood.V94.9.3234","article-title":"Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses","volume":"94","author":"Childs","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2009.03.006_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1704525","article-title":"Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme","volume":"34","author":"Khan","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib8","first-page":"7","article-title":"Report on the state of the art in blood and marrow transplantation. Part 1 of the IBMTR\/ABMTR summary slides with guide","volume":"10","author":"Loberiza","year":"2003","journal-title":"IBMTR\/ABMTR Newsletter"},{"key":"10.1016\/j.soncn.2009.03.006_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.transci.2004.10.006","article-title":"Hemopoietic chimerism following stem cell transplantation","volume":"32","author":"McCann","year":"2005","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.soncn.2009.03.006_bib10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0301-472X(03)00223-6","article-title":"Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection","volume":"31","author":"Canals","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.soncn.2009.03.006_bib11","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1182\/blood-2004-03-0804","article-title":"Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors","volume":"104","author":"Diaconescu","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2009.03.006_bib12","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bbmt.2004.10.008","article-title":"Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation","volume":"11","author":"Wong","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood-2004-02-0545","article-title":"Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities","volume":"104","author":"Sorror","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2009.03.006_bib14","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.bbmt.2007.04.004","article-title":"Comparable antileukemia\/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen","volume":"13","author":"Maruyama","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib15","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.critrevonc.2007.01.004","article-title":"Allogeneic hematopoietic stem cell transplantation in the elderly","volume":"64","author":"Shapira","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.soncn.2009.03.006_bib17","first-page":"6","article-title":"Non-myeloablative stem cell transplants","volume":"111","author":"Barrett","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.soncn.2009.03.006_bib18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1040-8428(01)00226-8","article-title":"Critical review on non-myeloablative stem cell transplantation (NST)","volume":"44","author":"Anagnostopoulos","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.soncn.2009.03.006_bib19","first-page":"241","article-title":"Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens","volume":"66","author":"Ruiz-Argulles","year":"2001","journal-title":"Am J\u00a0Hematol"},{"key":"10.1016\/j.soncn.2009.03.006_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/sj.bmt.1705923","article-title":"Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases","volume":"41","author":"Satwani","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib21","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1056\/NEJM200009143431101","article-title":"Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation","volume":"343","author":"Childs","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2009.03.006_bib22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/MOH.0b013e32831188f5","article-title":"Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose?","volume":"15","author":"Adkins","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.soncn.2009.03.006_bib23","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.bbmt.2007.03.011","article-title":"Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the National Marrow Donor Program","volume":"13","author":"Giralt","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/sj.bmt.1702875","article-title":"Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases","volume":"27","author":"Anderlini","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbmt.2006.10.015","article-title":"Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives","volume":"13","author":"Sandmaier","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2141.2006.06223.x","article-title":"Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used","volume":"134","author":"Ings","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.soncn.2009.03.006_bib27","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1182\/blood-2008-03-143677","article-title":"Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population","volume":"112","author":"Vasu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2009.03.006_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.bmt.1705388","article-title":"Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?","volume":"38","author":"Mehta","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib29","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2002-08-2628","article-title":"Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation","volume":"102","author":"Mielcarek","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2009.03.006_bib30","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/sj.leu.2404642","article-title":"Chronic graft-versus-host disease in the era of reduced-intensity conditioning","volume":"21","author":"Subramaniam","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.soncn.2009.03.006_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00001622-199903000-00003","article-title":"Reinventing bone marrow transplantation: Reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy","volume":"11","author":"Champlin","year":"1999","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.soncn.2009.03.006_bib32","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1046\/j.1365-2141.2001.02587.x","article-title":"Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility","volume":"112","author":"Bolan","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.soncn.2009.03.006_bib33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.bbmt.2008.01.003","article-title":"ABO incompatibility is associated with increased non-relapse and GVHD related mortality in patients with malignancies treated with a reduced intensity regimen: a single center experience of 221 patients","volume":"14","author":"Resnick","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jpsychores.2003.10.015","article-title":"Psychometric study of quality of life instruments used during hospitalization for stem cell transplantation","volume":"57","author":"Prieto","year":"2004","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.soncn.2009.03.006_bib35","first-page":"1243","article-title":"The symptom experience in the first 100 days following allogeneic hematopoietic stem cell transplantation (HSCT)","volume":"16","author":"Bevans","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.soncn.2009.03.006_bib36","first-page":"337","article-title":"Is reduced-intensity conditioning the standard of care in the transplant setting?","volume":"6","author":"Giralt","year":"2008","journal-title":"Clinical advances in hematology & oncology"},{"key":"10.1016\/j.soncn.2009.03.006_bib37","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.2006.09.7865","article-title":"Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation","volume":"25","author":"Sorror","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soncn.2009.03.006_bib38","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2007-07-098483","article-title":"Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia","volume":"111","author":"Sorror","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2009.03.006_bib39","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/sj.bmt.1704267","article-title":"Are predictive factors clinically useful in bone marrow transplantation?","volume":"32","author":"Bolwell","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib40","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bmt.1703382","article-title":"Is there an upper age limit for bone marrow transplantation?","volume":"29","author":"Popplewell","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib41","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.bmt.1704027","article-title":"Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality","volume":"31","author":"Robin","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib42","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/sj.bmt.1705041","article-title":"Comorbidity indices in hematopoietic stem cell transplantation: a new report card","volume":"36","author":"Alamo","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib43","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2009.03.006_bib44","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.bbmt.2008.06.008","article-title":"Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants","volume":"14","author":"Majhail","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib45","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.23375","article-title":"Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation","volume":"112","author":"Sorror","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.soncn.2009.03.006_bib46","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.bbmt.2006.05.015","article-title":"Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation","volume":"12","author":"Artz","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib47","first-page":"115","article-title":"Food and Drug Administration requirements for approval of new anticancer drugs","volume":"69","author":"Johnson","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.soncn.2009.03.006_bib48","series-title":"Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims","author":"Burke","year":"2006"},{"key":"10.1016\/j.soncn.2009.03.006_bib49","series-title":"Patient-reported outcomes measurement information system","year":"2008"},{"key":"10.1016\/j.soncn.2009.03.006_bib50","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/sj.bmt.1701998","article-title":"Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year?","volume":"24","author":"Hjermstad","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib51","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00006842-199201000-00006","article-title":"Long-term psychological adjustment of acute leukemia survivors: impact of bone marrow transplantation versus conventional chemotherapy","volume":"54","author":"Lesko","year":"1992","journal-title":"Psychosom Med"},{"key":"10.1016\/j.soncn.2009.03.006_bib52","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/archinte.1991.00400020114022","article-title":"A population-based study of functional status and social support networks of elderly patients newly diagnosed with cancer","volume":"151","author":"Goodwin","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.soncn.2009.03.006_bib53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/sj.bmt.1705406","article-title":"Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation","volume":"38","author":"Bevans","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib54","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.bmt.1704646","article-title":"Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic as compared to autologous transplantation: results of a prospective study","volume":"34","author":"Diez-Campelo","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib55","first-page":"75","article-title":"Physical and\u00a0psychosocial functioning of adult survivors of allogeneic bone marrow transplantation","volume":"4","author":"Andrykowski","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib56","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/sj.bmt.1700672","article-title":"Quality of life measurement in bone marrow transplantation: development of the functional assessment of cancer therapy-bone marrow transplant (FACT-BMT) scale","volume":"19","author":"McQuellon","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib57","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1523-5394.1999.74005.x","article-title":"Reintegration after\u00a0bone marrow transplantation","volume":"7","author":"Baker","year":"1999","journal-title":"Cancer Pract"},{"key":"10.1016\/j.soncn.2009.03.006_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1300\/J077v22n02_01","article-title":"Survival of patients who have undergone allogeneic bone marrow transplantation: the relative importance of in-hospital lay care-partner support","volume":"22","author":"Foster","year":"2004","journal-title":"J Psychosoc Oncol"},{"key":"10.1016\/j.soncn.2009.03.006_bib59","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/JCO.2000.18.1.64","article-title":"Predicting costs of stem-cell transplantation","volume":"18","author":"Lee","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soncn.2009.03.006_bib60","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbmt.2007.10.010","article-title":"Costs of allogeneic hematopoietic cell transplantation with high-dose regimens","volume":"14","author":"Saito","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib61","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/sj.bmt.1705733","article-title":"Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy","volume":"40","author":"Saito","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib62","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.bmt.1705109","article-title":"Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia","volume":"36","author":"Cordonnier","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib63","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/sj.bmt.1702100","article-title":"Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases","volume":"25","author":"Gomez-Almaguer","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.soncn.2009.03.006_bib64","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1182\/blood-2002-03-0801","article-title":"Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care","volume":"100","author":"Svahn","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2009.03.006_bib65","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/cncr.23444","article-title":"A gerontologic perspective on cancer and aging","volume":"112","author":"Blank","year":"2008","journal-title":"Cancer"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208109000254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208109000254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:52:51Z","timestamp":1760071971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208109000254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0749208109000254"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2009.03.006","relation":{},"ISSN":["0749-2081"],"issn-type":[{"value":"0749-2081","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2009.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}